These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34572915)

  • 1. CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women.
    Bergström H; Helde Frankling M; Klasson C; Lövgren Sandblom A; Diczfalusy U; Björkhem-Bergman L
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio.
    Mlugu EM; Minzi OM; Kamuhabwa AAR; Diczfalusy U; Aklillu E
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.
    Diczfalusy U; Nylén H; Elander P; Bertilsson L
    Br J Clin Pharmacol; 2011 Feb; 71(2):183-9. PubMed ID: 21219398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
    Suzuki Y; Oda A; Negami J; Toyama D; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Lipid Res; 2022 Mar; 63(3):100184. PubMed ID: 35181316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
    de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
    Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of effects of indoxyl sulfate and parathyroid hormone on CYP3A activity considering the influence of CYP3A5 gene polymorphisms.
    Oda A; Suzuki Y; Yoshijima C; Sato H; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Itoh H; Ohno K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3648-3658. PubMed ID: 37522799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
    Penzak SR; Rojas-Fernandez C
    J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.
    Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V
    Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.
    Taguchi R; Naito T; Kubono N; Ogawa N; Itoh H; Kawakami J
    Pregnancy Hypertens; 2019 Jul; 17():209-215. PubMed ID: 31487643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.
    Mannheimer B; Wagner H; Östenson CG; Diczfalusy U
    PLoS One; 2015; 10(4):e0121984. PubMed ID: 25835492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the usefulness of plasma 4β-hydroxycholesterol concentration normalized by 4α-hydroxycholesterol for accurate CYP3A phenotyping.
    Oda A; Suzuki Y; Sato H; Koyama T; Nakatochi M; Momozawa Y; Tanaka R; Ono H; Tatsuta R; Ando T; Shin T; Wakai K; Matsuo K; Itoh H; Ohno K
    Clin Transl Sci; 2024 Mar; 17(3):e13768. PubMed ID: 38465776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.
    Nylén H; Sergel S; Forsberg L; Lindemalm S; Bertilsson L; Wide K; Diczfalusy U
    Eur J Clin Pharmacol; 2011 Jul; 67(7):715-22. PubMed ID: 21246351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.
    Kim AH; Kim B; Rhee SJ; Lee Y; Park JS; Lee SM; Kim SM; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2018 Jun; 33(3):173-178. PubMed ID: 29759884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
    Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
    Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
    Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study.
    Björkhem-Bergman L; Nylén H; Norlin AC; Lindh JD; Ekström L; Eliasson E; Bergman P; Diczfalusy U
    Drug Metab Dispos; 2013 Apr; 41(4):704-8. PubMed ID: 23386704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
    Tahara H; Watanabe M; Hasegawa M
    Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Nylén H; Riedel KD; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2013 Dec; 13(6):484-9. PubMed ID: 23089673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
    Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
    AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.